What is the effect of rivaroxaban on routine coagulation tests?
نویسندگان
چکیده
A 78-year-old female presents to the emergency department with a traumatic hip fracture. Her past medical history is significant for atrial fibrillation for which she receives rivaroxaban 20 mg daily. Her dose was last taken 12 hours ago. Routine bloodwork conducted in the emergency department shows prothrombin time, international normalized ratio, and activated partial thromboplastin time within the normal range, and estimated glomerular filtration rate of 50 mL/min/1.73 m(2) (normal is >90 mL/min/1.73 m(2)) You are asked by the surgical team to confirm that it is safe to proceed with surgery at this time using neuraxial anesthesia.
منابع مشابه
Effects of Rivaroxaban on Coagulation Assays in Patients with Small Pulmonary Embolism and Deep Vein Thrombosis in Relation to Body Mass Index
Introduction: Rivaroxaban is a new anticoagulant medication for pulmonary thromboembolism (PTE) and deep vein thrombosis (DVT). There are limited data on the effect of body mass index (BMI) on the pharmacokinetics of rivaroxaban. This study aimed to assess the effect of rivaroxaban on coagulation assays in relation to BMI in PTE and DVT patients. Materials and Met...
متن کاملRivaroxaban and apixaban in orthopaedics: is there a difference in their plasma concentrations and anticoagulant effects?
The aim of this study was to improve knowledge of what happens in the coagulation of orthopaedic patients under rivaroxaban and apixaban, in order to finalize and cross-validate effective measurement methods and to provide arguments for helping to reference one or the other drug in our central pharmacy. One hundred and two patients undergoing total hip or knee replacement were included. Half of...
متن کاملDetecting clinically relevant rivaroxaban or dabigatran levels by routine coagulation tests or thromboelastography in a cohort of patients with atrial fibrillation
Background Traditional coagulation tests are included in emergency guidelines for management of patients on direct oral anticoagulants (DOACs) who experience acute bleeding or require surgery. We determined the ability of traditional coagulation tests and fast whole blood thromboelastography (ROTEM®) to screen for anticoagulation activity of dabigatran and rivaroxaban as low as 30 ng/mL. Meth...
متن کاملPractical guidance for using rivaroxaban in patients with atrial fibrillation: balancing benefit and risk
Rivaroxaban is a direct factor Xa inhibitor that is widely available to reduce the risk of stroke or systemic embolism in patients with nonvalvular atrial fibrillation and one or more risk factors for stroke. Rivaroxaban provides practical advantages compared with warfarin and other vitamin K antagonists, including a rapid onset of action, few drug interactions, no dietary interactions, a predi...
متن کاملHow I Treat How I treat target-specific oral anticoagulant–associated bleeding
Target-specific oral anticoagulants (TSOACs) that target thrombin (dabigatran) or factor Xa (rivaroxaban and apixaban) offer practical advantages over vitamin K antagonists (VKAs) for long-term oral anticoagulant therapy, including rapid onset of action, short halflives, fewer drug and food interactions, and predictable pharmacokinetics eliminating the need for routine monitoring of anticoagula...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- Hematology. American Society of Hematology. Education Program
دوره 2014 1 شماره
صفحات -
تاریخ انتشار 2014